MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.0012 UNCHANGED
Last Price Updated: 3:34 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Lexaria Appoints New Chief Financial Officer
Via ACCESSWIRE
News headline image
Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases ↗
 
Via Benzinga
News headline image
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
Via ACCESSWIRE
News headline image
Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $2M in Public Offering
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of cGMP Manufacturing for Upcoming Clinical Trial
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Announces 2023 Annual Meeting Results
Via ACCESSWIRE
News headline image
Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
Via ACCESSWIRE
News headline image
cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual Meeting
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
Via ACCESSWIRE
News headline image
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
Via ACCESSWIRE
News headline image
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
Via ACCESSWIRE
News headline image
Lexaria is Receiving Four New Patents
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Encouraging Results from DehydraTECH-CBD Diabetes Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels ↗
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) (NASDAQ: LEXXW) diabetes animal model study DIAB-A22-1 has been completed and produced at least three positive outcomes including weight loss in 
Via Benzinga
News headline image
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels
Via ACCESSWIRE
News headline image
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
Via ACCESSWIRE
News headline image
Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor
Via ACCESSWIRE
News headline image
Lexaria Releases Annual Letter from the CEO
Via ACCESSWIRE
News headline image
Lexaria Receives First Granted Patent in Canada
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD (TM) Achieves Superior CBD Blood Absorption Levels in Hypertension Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing in Its Human Oral Nicotine Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria’s Human Oral Nicotine Study Begins Dosing
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD(TM) Demonstrates Enhanced Performance Compared to Leading Anti-Seizure Medication
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program
Via ACCESSWIRE
News headline image
Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences 1st-Ever Study Evaluating DehydraTECH-CBD’s Effect on Diabetes
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story